Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Interactive Tools
Sponsored
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Global Perspective: CDK4/6 Inhibitors in HR+ Breast Cancer
EP. 1: The Spectrum of HR+ Breast Cancer: Approaching Treatment
July 26th 2018
EP. 2: Selecting Therapy for HR+ Breast Cancer
July 26th 2018
EP. 3: Considering CDK4/6 Inhibitors in Advanced Breast Cancer
July 26th 2018
EP. 4: HR+ Breast Cancer: Differences Between CDK4/6 Inhibitors
July 26th 2018
EP. 5: HR+ Breast Cancer: Prognostic Subgroups in MONARCH Trials
July 26th 2018
EP. 6: HR+ Breast Cancer: Risk-Stratifying to CDK4/6 Inhibitors
July 26th 2018
EP. 7: HR+ Breast Cancer: CDK4/6 Inhibitors & Sites of Metastasis
July 26th 2018
EP. 8: HR+ Breast Cancer: Factors in Selecting a CDK4/6 Inhibitor
July 26th 2018
EP. 9: Optimizing CDK4/6 Inhibition in HR+ Breast Cancer
July 26th 2018
EP. 10: Abemaciclib Monotherapy's Role in HR+ Breast Cancer
July 26th 2018
NEXT PAGE
<
1
2
>
PREVIOUS PAGE